Adicet Bio, Inc. Relocates Principal Executive Offices

TL;DR

Adicet Bio moved its HQ to Boston, MA.

AI Summary

On February 5, 2025, Adicet Bio, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 131 Dartmouth Street, Floor 3, Boston, Massachusetts 02116. The company previously operated under the name resTORbio, Inc. before changing its name on October 24, 2017.

Why It Matters

This filing signals a physical relocation of Adicet Bio's main operational base, which could impact logistics, employee access, and potentially future expansion plans.

Risk Assessment

Risk Level: low — The filing is a routine administrative update regarding office location and does not contain information about financial performance, material agreements, or regulatory actions.

Key Players & Entities

• Adicet Bio, Inc. (company) — Registrant
• resTORbio, Inc. (company) — Former company name
• February 05, 2025 (date) — Date of report
• October 24, 2017 (date) — Date of name change
• 131 Dartmouth Street, Floor 3, Boston, Massachusetts 02116 (location) — New principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma

Filing Documents

• acet-20250205.htm (8-K) — 47KB
• 0000950170-25-014153.txt ( ) — 160KB
• acet-20250205.xsd (EX-101.SCH) — 24KB
• acet-20250205_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. Clinical Trial Enrollment Updates On February 5, 2025, Adicet Bio, Inc. (Adicet or the Company) will participate in the Guggenheim Securities SMID Cap Biotech Conference held in New York City. During the conference, the Company will provide an update on the enrollment status of its clinical programs: ADI-001 Lupus Nephritis (LN) Program: The Company has enrolled 3 patients in its Phase 1 LN clinical trial for ADI-001, an allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting B cells via an anti-CD20 CAR. The Company dosed the first patient in the trial in November 2024, and approximately 12 sites have been activated to date, with additional sites anticipated in the near future. Phase 1 patient enrollment is ongoing, and the Company anticipates reporting preliminary results from the Phase 1 LN clinical trial in the first half of 2025. ADI-001 Additional Autoimmune Indications: The Company continues to expect to initiate Phase 1 patient enrollment in systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy and stiff person syndrome in the first quarter of 2025 with preliminary data from these patient cohorts in the second half of 2025. Patient enrollment in anti-neutrophil cytoplasmic autoantibody associated vasculitis is expected to begin in the second half of 2025. ADI-270 Metastatic/Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Program : The Company has enrolled 3 patients in its Phase 1 ccRCC program for ADI-270, an armored allogeneic gamma delta CAR T cell therapy candidate targeting CD70+ tumors. The Company dosed the first patient in the trial in December 2024, and approximately 7 sites have been activated to date, with additional sites anticipated in the near future. Phase 1 patient enrollment is ongoing, and the Company anticipates reporting preliminary results from the trial in the first half of 2025.

Forward-Looking Statements

Forward-Looking Statements The disclosure under this Item 8.01 contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Adicet's expectations regarding its Phase 1 trial of ADI-001 in LN, including plans to report preliminary data from the ongoing Phase 1 LN clinical trial in the first half of 2025 and additional site activation; its Phase 1 trial of ADI-001 in additional autoimmune indications, including plans to initiate patient enrollment in systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy and stiff person syndrome in the first quarter of 2025 and plans to report preliminary data from these cohorts in the second half of 2025; the initiation of patient enrollment for ADI-001 in anti-neutrophil cytoplasmic autoantibody associated vasculitis in the second half of 2025; and its Phase 1 trial of ADI-270 in ccRCC, including site activation and plans to report preliminary clinical data in the first half of 2025. Any forward-looking statements in this Item 8.01 are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health crises on the Company's business and financial results, including with respect to disrupt

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: February 5, 2025 By: /s/ Nick Harvey Name: Nick Harvey Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR